Key Takeaways
Amgen (NASDAQ: AMGN) shares experienced a notable dip on May 15, 2026, closing at $326.31, down 2.95% from its previous close of $336.23. This immediate market reaction was largely triggered by alarming reports from Japan concerning Tavneos (avacopan), a key drug in Amgen's portfolio. News outlets, citing Amgen's Japanese partner Kissei Pharmaceutical, reported that at least 20 people in Japan who took Tavneos have died, with another 22 developing potentially fatal liver injuries.
Tavneos is a crucial treatment for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a rare and life-threatening autoimmune disease. Amgen acquired the drug through its $3.7 billion purchase of ChemoCentryx in 2022, a year after Tavneos launched in the U.S. The drug's importance to Amgen's rare disease pipeline makes these safety concerns particularly impactful, especially as the U.S. Food and Drug Administration (FDA) had already flagged serious liver injury cases and requested Amgen voluntarily withdraw the drug earlier this year.
Kissei Pharmaceutical, which holds the rights to Tavneos in Japan, issued a safety notice urging doctors to stop prescribing the medication to new patients and to review ongoing treatments. This move underscores the gravity of the situation in Japan, where the drug has been prescribed to over 8,500 patients since its launch in 2022. The unfolding events highlight the inherent risks in pharmaceutical development and commercialization, where post-marketing surveillance can reveal new, severe adverse events not fully captured in clinical trials.
The core of the current controversy lies in the reported severe liver injuries and fatalities linked to Tavneos, particularly in Japan. Kissei Pharmaceutical's safety notice detailed 20 fatal cases of serious liver injury and 22 cases of potentially fatal liver injuries among Japanese patients. Some of these deaths were specifically tied to vanishing bile duct syndrome (VBDS), a rare but dangerous condition characterized by the progressive destruction of bile ducts, which can lead to permanent liver damage. Drug-induced liver injury (DILI) in general has been a central concern.
However, it's critical to contextualize these numbers. Amgen, in its statement, emphasized that these figures from Japan include cases where a causal relationship with Tavneos could not be definitively determined. Furthermore, Amgen stated there have been no known deaths in the U.S. linked to serious liver injury, including VBDS, among the more than 8,000 patients treated with Tavneos in the U.S. since its approval in 2021. This stark contrast suggests potential regional differences in patient populations, co-medications, or reporting standards.
The FDA's own review, incorporating global safety data through October 9, 2024, identified 76 cases of DILI with a reasonable causal association with avacopan use. Of these, 74 resulted in serious outcomes, including 54 hospitalizations and 8 deaths. A noteworthy geographical distribution emerged: 66 of these 76 cases were reported from Japan, compared to just 5 from the United States, 4 from Europe, and 1 from Canada. Experts suggest that a higher background rate of liver toxicity in Japan and broader prescription rates there might contribute to this disparity. While hepatotoxicity was a known risk from the ADVOCATE trial, the emergence of VBDS and fatal DILI outcomes in real-world post-marketing settings represents new, more severe safety concerns.
The regulatory scrutiny surrounding Tavneos intensified well before the recent Japanese reports. In March 2026, the FDA issued a safety communication alerting healthcare professionals and patients to serious postmarketing cases of DILI, including fatal cases, associated with Tavneos. This communication followed an earlier request in January 2026 for Amgen to voluntarily withdraw Tavneos from the U.S. market, a request that Amgen declined, citing its confidence in the drug's benefit-risk profile.
Amgen has consistently defended Tavneos, asserting that it remains an important and effective medicine for ANCA-associated vasculitis, a disease with high mortality rates if left untreated. The company's stance is rooted in the Phase 3 ADVOCATE trial, which demonstrated Tavneos's non-inferiority to prednisone in achieving remission at week 26 (72.3% vs. 70.1%) and superiority in sustaining remission at week 52 (65.7% vs. 54.9%). Amgen highlights that the U.S. prescribing information has always included warnings about serious liver injury (hepatotoxicity) and provides specific liver monitoring guidance for physicians.
Despite Amgen's defense, the FDA has since moved to formally begin withdrawal proceedings, indicating a significant regulatory challenge ahead. The agency's concerns extend beyond the newly reported fatalities to questions about the assessment of primary endpoints in the ADVOCATE trial. Amgen continues to engage with the FDA, emphasizing its commitment to patient safety and ongoing support for the ANCA-associated vasculitis community. This regulatory tug-of-war underscores the high stakes involved for both patient safety and Amgen's commercial interests.
The implications of the Tavneos safety concerns extend far beyond clinical discussions, posing significant financial and reputational risks for Amgen. The immediate stock price drop on May 15 is just a glimpse of potential future volatility. With a market capitalization of $176.11 billion, Amgen is a pharmaceutical giant, but even large companies are susceptible to the fallout from drug safety issues.
Three key areas of risk stand out:
Regulatory Action and Sales Impact: If the FDA proceeds with formal withdrawal, or if other major regulatory bodies follow suit, Tavneos sales would plummet. While Amgen does not break out Tavneos revenue specifically, it's a relatively new drug from a $3.7 billion acquisition, indicating its strategic importance. Even without a full withdrawal, increased monitoring requirements, stricter prescribing guidelines, or a "black box" warning could severely limit its market penetration and growth potential. The company's ability to defend the drug's benefit-risk profile against regulatory pressure will be crucial in mitigating this risk.
Litigation and Settlements: The reported deaths and liver injuries, particularly the 8 fatalities identified by the FDA and the 20 deaths in Japan, open the door to potential lawsuits. Patients and their families may pursue claims for drug-induced liver injury, VBDS, and wrongful death. Such litigation can be protracted and costly, leading to substantial legal fees, settlement payouts, and adverse judgments. The legal landscape is already active, with investigations into Tavneos lawsuits underway in 2026.
Reputational Damage: Beyond direct financial costs, the negative publicity surrounding Tavneos can erode trust among healthcare providers, patients, and investors. Amgen's brand, built on innovation and patient care, could suffer. Rebuilding this trust requires transparent communication, proactive safety measures, and a clear demonstration of commitment to patient well-being. The long-term impact on Amgen's ability to launch new drugs or attract talent could be significant if its reputation is tarnished.
For investors, the Tavneos situation presents a complex risk-reward profile, leading to distinct bull and bear cases for Amgen's stock.
The Bull Case: Optimists point to Amgen's robust pipeline and diversified portfolio. Tavneos, while important, is not the sole driver of Amgen's revenue. The company has a strong foundation with established blockbuster drugs and a promising pipeline of new therapies. Amgen's recent financial results, including its Q1 2026 earnings, reflect a company with significant operational strength. Furthermore, the rarity and severity of ANCA-associated vasculitis mean that Tavneos addresses a critical unmet medical need. If Amgen can successfully argue that the benefits outweigh the risks, especially with proper monitoring, and if the Japanese cases are indeed outliers due to specific regional factors, the drug could retain its market position. The company's assertion of no known deaths in the U.S. from Tavneos-related liver injury provides a strong counter-narrative.
The Bear Case: Pessimists highlight the escalating regulatory pressure and the potential for widespread litigation. The FDA's move to formally initiate withdrawal proceedings is a serious escalation, suggesting that Amgen's defense may not be sufficient to satisfy regulators. The reports of 20 deaths in Japan, even if causality is debated, create a powerful negative sentiment. If Tavneos is withdrawn from major markets, Amgen would face a significant financial hit, not just from lost sales but also from the write-down of the $3.7 billion acquisition. The specter of a class-action lawsuit or numerous individual claims could result in billions in liabilities, overshadowing the company's other successes. Moreover, the reputational damage could have long-lasting effects on physician prescribing habits and investor confidence.
For investors holding or considering Amgen shares, the Tavneos situation introduces a layer of uncertainty that demands careful monitoring. The stock's current price of $326.31 reflects some of this concern, but the full impact remains to be seen. Key catalysts to watch include further communications from the FDA, the outcome of any formal withdrawal proceedings, and developments in potential litigation.
Investors should evaluate Amgen's overall financial health, beyond just Tavneos. The company's ability to innovate, manage its broader pipeline, and execute on its strategic initiatives will ultimately determine its long-term value. While the immediate headlines are concerning, Amgen's diversified revenue streams and strong market position provide a degree of resilience. However, the Tavneos issue serves as a stark reminder of the inherent risks in the pharmaceutical sector, where a single drug's safety profile can significantly impact investor sentiment and corporate value.
The coming months will be critical for Amgen as it navigates these regulatory and public relations challenges. Investors should remain vigilant, paying close attention to official statements from Amgen and regulatory bodies, as well as any new data emerging from post-marketing surveillance. The resolution of this issue will provide clearer direction on Amgen's future trajectory and the true cost of the Tavneos controversy.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
